Equine Protozoal Myeloencephalitis: Diagnosis and Treatment Challenges

Introduction

Equine protozoal myeloencephalitis (EPM) is a debilitating neurologic disease of horses caused primarily by the apicomplexan parasite Sarcocystis neurona. Less commonly, Neospora hughesi has been implicated. The disease manifests as asymmetric ataxia, muscle atrophy, and cranial nerve deficits, reflecting multifocal inflammation of the central nervous system (CNS). Despite decades of research, EPM remains a diagnostic and therapeutic challenge due to the limitations of antemortem testing, the blood-brain barrier (BBB) restricting drug penetration, and the parasite's ability to persist within the CNS. This article reviews the current understanding of EPM diagnosis and treatment, emphasizing the biophysical and immunological mechanisms underlying assay performance and therapeutic efficacy.

Etiology and Pathogenesis

S. neurona is an obligate intracellular protozoan with a heteroxenous life cycle. The definitive host is the opossum (Didelphis virginiana), which sheds sporocysts in feces. Horses are aberrant intermediate hosts, acquiring infection through ingestion of sporocyst-contaminated feed or water. Following ingestion, sporozoites excyst, invade the intestinal epithelium, and disseminate hematogenously. The parasite crosses the BBB via mechanisms involving rhoptry proteins such as SnROP9, a homologue expressed in lifecycle stages lacking rhoptry organelles [1]. Once within the CNS, S. neurona undergoes schizogony in neurons and microglial cells, eliciting a Th1-biased immune response characterized by IgG subclasses and interferon-gamma production [2]. The resultant inflammation leads to demyelination, axonal degeneration, and gliosis, producing the classic clinical signs.

Seroprevalence studies indicate widespread exposure. In Alberta, Canada, healthy horses showed seropositivity rates of 45% for S. neurona and 8% for N. hughesi using indirect fluorescent antibody tests (IFAT) [3]. Similar rates have been reported in Brazil, where cross-reactivity with Sarcocystis falcatula-like organisms complicates serological interpretation [4]. Importantly, seropositivity alone does not confirm EPM; only a minority of seropositive horses develop neurologic disease.

Clinical Signs

EPM typically presents as a progressive, asymmetric, multifocal neurologic disorder. Common signs include:

• Asymmetric ataxia and paresis, often worse in the hind limbs.
• Muscle atrophy, particularly of the gluteal and epaxial muscles.
• Cranial nerve deficits: facial nerve paralysis, dysphagia, head tilt.
• Proprioceptive deficits: knuckling, toe dragging, abnormal limb placement.
• Seizures or altered mentation in severe cases.

Differential diagnoses include West Nile Virus encephalomyelitis, equine herpesvirus-1 myeloencephalopathy, cervical vertebral stenotic myelopathy (CVSM), and trauma. A retrospective study of 171 cases of equine meningoencephalomyelitis in the United States identified EPM as one of the most common infectious causes, underscoring the need for accurate diagnostic differentiation [5].

Diagnostic Challenges

Antemortem diagnosis of EPM relies on a combination of neurologic examination, cerebrospinal fluid (CSF) analysis, and serological testing. No single test provides definitive confirmation, and each modality has inherent limitations.

Serology

Serum antibody testing for S. neurona is highly sensitive but poorly specific for active CNS infection. The IFAT and enzyme-linked immunosorbent assays (ELISA) detect exposure but cannot distinguish between past infection, latent carriage, and active disease. Pre-analytical variables affect titer accuracy. Refrigeration and room temperature storage, as well as delayed processing, can alter serum IFAT titers for S. neurona [6]. Long-term freezing of samples also impacts IFAT titers, potentially leading to false-negative results [7]. The SarcoFluor antibody test, a modified IFAT, has been re-evaluated for diagnostic performance, showing improved specificity when used with CSF rather than serum [8].

CSF Immunoblotting

The Western blot (immunoblot) for S. neurona antibodies in CSF has been a cornerstone of EPM diagnosis. The test detects intrathecal antibody production, which is more indicative of CNS infection than serum titers alone. However, false positives can occur due to blood contamination of CSF or passive diffusion of serum antibodies across a compromised BBB. The sensitivity of CSF immunoblotting ranges from 70% to 90%, with specificity around 80% to 90%. The test does not differentiate between active and resolved infection, and some horses with chronic EPM may have negative immunoblots due to sequestration of antibody within the parenchyma.

Polymerase Chain Reaction (PCR)

Real-time PCR targeting S. neurona DNA in CSF offers the advantage of detecting the parasite directly, confirming active infection. A study evaluating real-time PCR for EPM diagnosis using CSF reported moderate sensitivity (approximately 60%) but high specificity (greater than 95%) [9]. The low sensitivity is attributed to intermittent shedding of parasites into the CSF and the small volume of sample typically collected. PCR is most useful when combined with serological testing in a Bayesian diagnostic framework.

Ancillary Diagnostics

Magnetic resonance imaging (MRI) and myelography can identify compressive lesions that mimic EPM. Cervical spinal cord compression, as assessed during myelography, may affect anesthetic recovery quality and seizure incidence in horses, complicating the diagnostic workup [10]. CSF cytology often reveals mild mononuclear pleocytosis and elevated protein, but these findings are non-specific.

Diagnostic Algorithm

The following Mermaid diagram outlines a recommended diagnostic approach for suspected EPM.

flowchart TD
    A[Neurologic exam: asymmetric ataxia, cranial nerve deficits], > B{CSF analysis}
    B, > C[CSF immunoblot for S. neurona antibodies]
    B, > D[CSF real-time PCR for S. neurona DNA]
    C, > E{Immunoblot positive?}
    D, > F{PCR positive?}
    E, >|Yes| G[High probability of EPM]
    E, >|No| H[Low probability; consider alternative diagnoses]
    F, >|Yes| G
    F, >|No| I[Equivocal; repeat CSF tap or perform serum IFAT]
    I, > J{Serum IFAT titer >= 1:500?}
    J, >|Yes| G
    J, >|No| H
    G, > K[Initiate antiprotozoal therapy]
    H, > L[Investigate CVSM, EHV-1, WNV, trauma]

Treatment Challenges

Medical management of EPM aims to eliminate the parasite from the CNS while controlling inflammation. The ideal drug must cross the BBB, achieve therapeutic concentrations in neural tissue, and have a high margin of safety for horses. Currently approved and investigational agents face significant pharmacokinetic and pharmacodynamic hurdles.

Triazine Antiprotozoals

Ponazuril (toltrazuril sulfone) is the most widely used triazine anticoccidial for EPM. It inhibits dihydroorotate dehydrogenase in the pyrimidine biosynthesis pathway of apicomplexans. Oral administration of ponazuril achieves variable CSF penetration; the CSF-to-plasma concentration ratio is approximately 0.1 to 0.2. Standard dosing (5 mg/kg orally once daily for 28 days) yields clinical improvement in 60% to 70% of cases, but complete resolution is less common. A residue depletion study of ponazuril in pigs provided pharmacokinetic data relevant to withdrawal interval estimation, though equine-specific tissue residue data remain limited [11].

Diclazuril, another triazine, has been evaluated for CSF pharmacokinetics in healthy adult horses. After a single oral dose administered as a pelleted topdressing, diclazuril reached measurable concentrations in plasma and CSF, though CSF levels were lower than those of ponazuril [12]. The clinical efficacy of diclazuril for EPM has not been rigorously established in large trials.

Bumped-Kinase Inhibitors

A novel class of antiprotozoal agents, bumped-kinase inhibitors (BKIs), targets calcium-dependent protein kinases unique to apicomplexans. Pharmacokinetic analysis of BKIs in horses demonstrated favorable oral bioavailability and CNS penetration, suggesting potential utility for both prevention and treatment of EPM [13]. These compounds are not yet commercially available but represent a promising avenue for overcoming resistance and improving therapeutic outcomes.

Compounding and Formulation Issues

The limited number of FDA-approved equine antiprotozoal drugs has led to widespread use of compounded formulations. Compounding of ponazuril and other triazines raises concerns about drug stability, bioavailability, and consistency. Bethel [14] discussed the challenges of modern compounding for EPM, emphasizing the need for rigorous quality control to ensure therapeutic equivalence.

Adjunctive Therapy

Corticosteroids (e.g., dexamethasone) are often used to reduce CNS inflammation during the initial phase of treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs) may provide symptomatic relief but do not address the underlying infection. Vitamin E supplementation is commonly recommended for its antioxidant properties, though evidence of efficacy is anecdotal.

Treatment Monitoring and Duration

Response to therapy is assessed by serial neurologic examinations. A minimum of 28 days of antiprotozoal treatment is standard, but many horses require 90 to 120 days or longer. Relapse rates are high, possibly due to persistence of S. neurona within the CNS. Helber et al. [15] demonstrated persistence of S. neurona organisms and associated histopathology in horses with EPM despite treatment, indicating that current regimens may not achieve complete parasite clearance.

Prognosis

Prognosis for EPM is guarded. Factors associated with a favorable outcome include early diagnosis, mild neurologic deficits at presentation, and completion of a full course of therapy. Horses with severe ataxia, marked muscle atrophy, or cranial nerve deficits have a poorer prognosis. Approximately 20% to 30% of treated horses return to their previous level of athletic function, while others may have residual deficits. Euthanasia is considered for non-responsive cases or those with rapid deterioration.

Conclusion

Equine protozoal myeloencephalitis remains a formidable diagnostic and therapeutic challenge in equine medicine. Advances in molecular diagnostics, including real-time PCR and refined immunoblotting techniques, have improved antemortem detection, but no single test is definitive. Treatment with triazine antiprotozoals such as ponazuril is moderately effective, hampered by incomplete CNS penetration and parasite persistence. Emerging therapies, including bumped-kinase inhibitors, offer hope for more effective and safer regimens. Future research should focus on biomarker discovery for active CNS infection, optimized dosing strategies, and novel drug delivery systems to overcome the BBB.

References

[1] Jegatheesan A, Micciche M, Ngo J, et al. Characterization of SnROP9, a rhoptry protein homologue of Sarcocystis neurona that is expressed in lifecycle stages lacking rhoptry organelles. Int J Parasitol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39993621/

[2] Angwin CJ, de Assis Rocha I, Reed SM, et al. Analysis of IgG responses to Sarcocystis neurona in horses with equine protozoal myeloencephalitis (EPM) suggests a Th1-biased immune response. Vet Immunol Immunopathol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41016329/

[3] Sjolin E, Zakia LS, Galezowski A, et al. Seroprevalence of Sarcocystis neurona and Neospora hughesi in healthy horses from the province of Alberta, Canada. J Vet Intern Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41934607/

[4] Silva TMVD, De Santi M, Gonçalves LR, et al. Reactivity against Sarcocystis neurona and Sarcocystis falcatula-like in horses from Southeastern and Midwestern Brazil. Rev Bras Parasitol Vet. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37283358/

[5] Countrymann K, Ruby R, Miller AD. A retrospective study of 171 cases of equine meningoencephalomyelitis in the United States, 1996-2023. J Vet Diagn Invest. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/40988382/

[6] Valderrama-Martinez C, Packham A, Zheng S, et al. Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona. J Vet Intern Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39715359/

[7] Valderrama-Martinez C, Packham A, Smith W, et al. Effect of Long-Term Freezing on Indirect Fluorescent Antibody Titers for the Diagnosis of Equine Protozoal Myeloencephalitis. J Vet Intern Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40873183/

[8] Pandit PS, Smith WA, Finno CJ, et al. A fresh look at the SarcoFluor antibody test for the detection of specific antibodies to Sarcocystis neurona for the diagnosis of equine protozoal myeloencephalitis. Vet Parasitol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38897057/

[9] Enriquez CK, Morrow JK, Graves A, et al. Evaluation of real-time polymerase chain reaction for the diagnosis of protozoal myeloencephalitis in horses using cerebrospinal fluid. J Vet Intern Med. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37549306/

[10] Theiss D, Douglas HF, Colmer SF, et al. Cervical spinal cord compression may affect anesthetic recovery quality and seizure incidence in horses after myelography. Am J Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42248194/

[11] Neumann LM, Sheela F, Enomoto H, et al. Toltrazuril sulfone (Ponazuril) residue depletion in pig tissues and estimated withdrawal intervals. Regul Toxicol Pharmacol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40441282/

[12] Treece EJ, Hepworth-Warren KL, Papich MG, et al. Pharmacokinetics of Diclazuril in the Plasma and Cerebrospinal Fluid of Healthy Adult Horses After a Single Oral Dose Administered as a Pelleted Topdressing. J Vet Pharmacol Ther. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42141970/

[13] Rocha IA, McPeek JL, Hulverson MA, et al. Pharmacokinetic analysis of bumped-kinase inhibitors in horses demonstrates their potential utility for prevention and treatment of equine protozoal myeloencephalitis. Am J Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41086839/

[14] Bethel M. Equine Protozoal Myeloencephalitis: An Ancient Parasite Meets Modern Compounding. Int J Pharm Compd. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41819129/

[15] Helber L, Wagner B, Leeth CM, et al. Persistence of Sarcocystis neurona and histopathology in horses with equine protozoal myeloencephalitis. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42063422/